

Calithera Biosciences, Inc.  
Form 3  
October 01, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Â Molineaux Susan  
 (Last) (First) (Middle)  
 2. Date of Event Requiring Statement  
 (Month/Day/Year)  
 10/01/2014  
 3. Issuer Name and Ticker or Trading Symbol  
 Calithera Biosciences, Inc. [CALA]  
 4. Relationship of Reporting Person(s) to Issuer  
 5. If Amendment, Date Original Filed(Month/Day/Year)

C/O CALITHERA  
 BIOSCIENCES, INC.,Â 343  
 OYSTER POINT BLVD. #200  
 (Street)

(Check all applicable)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 PRESIDENT AND CEO

SOUTH SAN FRANCISCO,Â CAÂ 94080  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	106,962	I	By Trust <sup>(1)</sup>
Common Stock	11,000	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	--	---------------------------	----------------------	---

Edgar Filing: Calithera Biosciences, Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	12/13/2021	Common Stock	19,649	\$ 0.48	D	Â
Stock Option (Right to Buy)	Â (3)	06/12/2022	Common Stock	24,252	\$ 0.48	D	Â
Stock Option (Right to Buy)	Â (4)	05/22/2023	Common Stock	45,405	\$ 0.96	D	Â
Stock Option (Right to Buy)	Â (5)	12/16/2023	Common Stock	115,713	\$ 2.64	D	Â
Stock Option (Right to Buy)	Â (6)	09/08/2024	Common Stock	63,716	\$ 7.2	D	Â
Stock Option (Right to Buy)	Â (7)	05/22/2023	Common Stock	39,011	\$ 0.96	I	By Spouse
Stock Option (Right to Buy)	Â (8)	12/16/2023	Common Stock	34,033	\$ 2.64	I	By Spouse
Stock Option (Right to Buy)	Â (9)	09/08/2024	Common Stock	18,740	\$ 7.2	I	By Spouse

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Molineaux Susan C/O CALITHERA BIOSCIENCES, INC. 343 OYSTER POINT BLVD. #200 SOUTH SAN FRANCISCO, CA 94080	Â X	Â	Â PRESIDENT AND CEO	Â

## Signatures

/s/ Susan M. Molineaux 10/01/2014

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares and shares issuable pursuant to stock options, as applicable, are held by Molineaux Family Trust Dated Nov. 9, 2000, of which Reporting Person is a Trustee.
- (2) 1/48 of the Option vests in equal monthly installments one month from 11/07/2011. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

## Edgar Filing: Calithera Biosciences, Inc. - Form 3

- (3) 1/48 of the Option vests in equal monthly installments one month from 03/27/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (4) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (5) 1/48 of the Option vests in equal monthly installments one month from 09/09/2014. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (6) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- (7) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (8) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.
- (9) 1/48 of the Option vests in equal monthly installments one month from 09/09/2013. The option shall be subject to accelerated vesting as set forth in such optionee's employment agreement with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.